文献速递流行病学与生物统计真实世界研究与卫生经济

澳大利亚消除工业反式脂肪酸的健康收益、成本与成本效果:模型研究

Estimated health benefits, costs, and cost-effectiveness of eliminating industrial trans-fatty acids in Australia: A modelling study.
PubMed 文献 · PLoS Med · 2020-11-02

该建模研究评估澳大利亚全国禁止工业反式脂肪酸(iTFA)对缺血性心脏病(IHD)负担、健康公平和成本效果的影响。结果显示,禁令预计在10年内预防2294例IHD死亡和9931例IHD事件,健康收益最大的是社会经济最弱势群体和主要城市以外居民;干预具有成本节约或成本效果,且结果在敏感性分析中稳健。

要点

  • 全国禁止iTFA预计10年内预防2294例IHD死亡和9931例IHD事件。
  • 健康收益最大的是社会经济最弱势五分位和主要城市以外居民。
  • 干预具有成本节约或成本效果,10年ICER为1073 AUD/HALY。

核心结论

  • 模型估计澳大利亚禁止iTFA可避免大量IHD事件和死亡,且很可能是极具成本效果的减少健康社会经济和城乡不平等策略。
  • 即使iTFA摄入量低的国家,消除iTFA也可成本有效地改善健康和健康公平。

研究设计与样本

  • 采用马尔可夫队列模型估计全国禁止iTFA对IHD负担、健康公平和成本效果的影响。
  • TFA摄入量基于2011-2012年澳大利亚国家营养与身体活动调查评估。
  • IHD归因负担通过比较当前TFA摄入与理论最低分布(日均能量0.5%,仅非工业来源)计算。
  • 估计10年和终生时间范围内政策成本、避免的IHD事件和死亡、获得的健康调整生命年(HALYs)及IHD相关医疗成本节省。
  • 成本效果通过净政策成本和获得的HALYs计算增量成本效果比(ICERs)评估。

主要发现

  • 与无禁令且当前TFA摄入的基线相比,消除iTFA预计在头10年预防2294例(95%不确定性区间[UI]:1765;2851)IHD死亡和9931例(95% UI:8429;11532)IHD事件。
  • 健康收益最大的是社会经济最弱势五分位和居住在主要城市以外的澳大利亚人。
  • 无论时间范围如何,干预估计为成本节约(净成本<0 AUD)或成本效果(ICER<169361 AUD/HALY),10年和终生ICER分别为1073(95% UI:dominant;3503)和1956(95% UI:1010;2750)AUD/HALY。
  • 结果在多项敏感性分析中稳健。

临床怎么用

  • 模型结果支持将全国禁止iTFA作为成本有效地改善IHD负担和健康公平的公共卫生策略。
  • 政策实施可优先关注社会经济弱势群体和主要城市以外居民以最大化健康收益和公平性。

局限性

  • 缺乏近期TFA摄入数据。
  • 用于估计亚组摄入量的样本量小。
  • 作为模拟模型,研究不能证明禁止iTFA会预防IHD,而是在缺乏更强直接证据时提供最佳定量估计和相应不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: trans-fatty acids (TFAs) are a well-known risk factor of ischemic heart disease (IHD). In Australia, the highest TFA intake is concentrated to the most socioeconomically disadvantaged groups. Elimination of industrial TFA (iTFA) from the Australian food supply could result in reduced IHD mortality and morbidity while improving health equity. However, such legislation could lead to additional costs for both government and food industry. Thus, we assessed the potential cost-effectiveness, health gains, and effects on health equality of an iTFA ban from the Australian food supply. METHODS AND FINDINGS: Markov cohort models were used to estimate the impact on IHD burden and health equity, as well as the cost-effectiveness of a national ban of iTFA in Australia. Intake of TFA was assessed using the 2011-2012 Australian National Nutrition and Physical Activity Survey. The IHD burden attributable to TFA was calculated by comparing the current level of TFA intake to a counterfactual setting where consumption was lowered to a theoretical minimum distribution with a mean of 0.5% energy per day (corresponding to TFA intake only from nonindustrial sources, e.g., dairy foods). Policy costs, avoided IHD events and deaths, health-adjusted life years (HALYs) gained, and changes in IHD-related healthcare costs saved were estimated over 10 years and lifetime of the adult Australian population. Cost-effectiveness was assessed by calculation of incremental cost-effectiveness ratios (ICERs) using net policy cost and HALYs gained. Health benefits and healthcare cost changes were also assessed in subgroups based on socioeconomic status, defined by Socio-Economic Indexes for Areas (SEIFA) quintile, and remoteness. Compared to a base case of no ban and current TFA intakes, elimination of iTFA was estimated to prevent 2,294 (95% uncertainty interval [UI]: 1,765; 2,851) IHD deaths and 9,931 (95% UI: 8,429; 11,532) IHD events over the first 10 years. The greatest health benefits were accrued to the most socioeconomically disadvantaged quintiles and among Australians living outside of major cities. The intervention was estimated to be cost saving (net cost <0 AUD) or cost-effective (i.e., ICER < AUD 169,361/HALY) regardless of the time horizon, with ICERs of 1,073 (95% UI: dominant; 3,503) and 1,956 (95% UI: 1,010; 2,750) AUD/HALY over 10 years and lifetime, respectively. Findings were robust across several sensitivity analyses. Key limitations of the study include the lack of recent data of TFA intake and the small sample sizes used to estimate intakes in subgroups. As with all simulation models, our study does not prove that a ban of iTFA will prevent IHD, rather, it provides the best quantitative estimates and corresponding uncertainty of a potential effect in the absence of stronger direct evidence. CONCLUSIONS: Our model estimates that a ban of iTFAs could avert substantial numbers of IHD events and deaths in Australia and would likely be a highly cost-effective strategy to reduce social-economic and urban-rural inequalities in health. These findings suggest that elimination of iTFA can cost-effectively improve health and health equality even in countries with low iTFA intake.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Marklund M, Zheng M, Veerman JL, et al. Estimated health benefits, costs, and cost-effectiveness of eliminating industrial trans-fatty acids in Australia: A modelling study. PLoS Med. 2020. PMID: 33137090. doi:10.1371/journal.pmed.1003407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。